Current Cancer Drug Targets


Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204


Meet Our Editorial Board Member free to download

Volume:17   Issue:2
Pp: 99-99
William Cho
DOI: 10.2174/156800961702170109213433

Anticancer Potential and Molecular Targets of Pristimerin: A Mini- Review

Volume:17   Issue:2
Pp: 100-108
Bashir A. Yousef, Hozeifa M. Hassan, Lu-Yong Zhang and Zhen-Zhou Jiang
DOI: 10.2174/1568009616666160112105824

Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors

Volume:17   Issue:2
Pp: 109-121
Alessandro Federico, Silvia Zappavigna, Marcello Dallio, Gabriella Misso, Francesco Merlino, Carmela Loguercio, Ettore Novellino, Paolo Grieco and Michele Caraglia
DOI: 10.2174/1568009616666160621101248

Current Development of ROS-Modulating Agents as Novel Antitumor Therapy

Volume:17   Issue:2
Pp: 122-136
Nan Wang, Yue Wu, Jinlei Bian, Xue Qian, Hongzhi Lin, Haopeng Sun, Qidong You and Xiaojin Zhang
DOI: 10.2174/1568009616666160216125833

CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma

Volume:17   Issue:2
Pp: 191-197
Xiaoqing Jia, Guangyu Liu, Jingyi Cheng, Zhenzhou Shen and Zhimin Shao
DOI: 10.2174/1568009616666160426125058